Lipocine (LPCN)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	3.74 mm	3.74 mm	3.74 mm	3.74 mm	3.74 mm	3.74 mm
Cash burn (monthly)	603.48 k	27.48 k	876.82 k	416.88 k	944.30 k	412.12 k
Cash used (since last report)	3.07 mm	139.69 k	4.46 mm	2.12 mm	4.80 mm	2.09 mm
Cash remaining	675.33 k	3.60 mm	-714.16 k	1.62 mm	-1.06 mm	1.65 mm
Runway (months of cash)	1.1	131.1	-0.8	3.9	-1.1	4.0

Beta Read what these cash burn values mean

Financial data from Lipocine earnings reports.

Institutional ownership, Q3 2024

LPCN institutional ownership history Ownership history

9.3% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	12	19	-36.8%
Opened positions	2	4	-50.0%
Closed positions	9	3	+200.0%
Increased positions	4	6	-33.3%
Reduced positions	0	5	EXIT

13F shares	Current	Prev Q	Change
Total value	2.23 bn	4.38 bn	-49.1%
Total shares	496.71 k	531.61 k	-6.6%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Vanguard	221.46 k	$994.35 mm	0.0%
BlackRock	89.27 k	$400.83 mm	NEW
UBS UBS	59.41 k	$266.76 mm	+5.7%
Geode Capital Management	54.22 k	$243.47 mm	+2.0%
Renaissance Technologies	40.33 k	$181.09 mm	+57.0%
Dimensional Fund Advisors	18.02 k	$80.89 mm	+51.8%
NTRS Northern Trust	13.16 k	$59.09 mm	0.0%
Caldwell Sutter Capital	471.00	$2.12 mm	0.0%
Advisor	227.00	$1.02 mm	0.0%
Clearstead Advisors	74.00	$333.00 k	0.0%

Largest transactions	Shares	Bought/sold	Change
BlackRock	89.27 k	+89.27 k	NEW
BLK BlackRock	0.00	-89.27 k	EXIT
Susquehanna International	0.00	-25.00 k	EXIT
STT State Street	0.00	-18.63 k	EXIT
Renaissance Technologies	40.33 k	+14.64 k	+57.0%
Two Sigma Advisers	0.00	-12.82 k	EXIT
Dimensional Fund Advisors	18.02 k	+6.15 k	+51.8%
UBS UBS	59.41 k	+3.19 k	+5.7%
MS Morgan Stanley	0.00	-2.63 k	EXIT
Geode Capital Management	54.22 k	+1.04 k	+2.0%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

LPCN insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
2 Jan 25	Mahesh V. Patel	Stock Option Common Stock	Grant	Acquire A	No	No	4.86	16,371	79.56 k	149,039
23 Dec 24	Mahesh V. Patel	Stock Option Common Stock	Grant	Acquire A	No	No	4.8	10,320	49.54 k	132,688
23 Dec 24	Krista Fogarty	Stock Option Common Stock	Grant	Acquire A	No	No	4.8	5,943	28.53 k	19,460
23 Dec 24	Mahesh V. Patel	Stock Option Common Stock	Grant	Acquire A	No	No	4.8	26,691	128.12 k	149,039
5 Jun 24	Higuchi John W.	Common Stock Common Stock	Grant	Acquire A	No	No	7.05	1,764	12.44 k	10,938

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

Press releases

From Benzinga Pro

Lipocine Receives Updated Regulatory Guidance on LPCN 1154

6 Feb 25

SALT LAKE CITY, Feb. 6, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today

FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis

17 Dec 24

SALT LAKE CITY, Dec. 17, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today